Detalhe da pesquisa
1.
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
Oncologist
; 29(5): e622-e634, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175669
2.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38587643
3.
Biomarkers of immunotherapy response in breast cancer beyond PD-L1.
Breast Cancer Res Treat
; 191(1): 39-49, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34676466
4.
Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease.
Ann Hematol
; 100(12): 2997-3005, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34463804
5.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Lancet Oncol
; 21(11): 1455-1464, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33152285
6.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Breast Cancer Res
; 22(1): 45, 2020 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32404150
7.
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
NPJ Breast Cancer
; 10(1): 20, 2024 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448600
8.
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.
Nat Commun
; 15(1): 3552, 2024 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38670972
9.
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.
EBioMedicine
; 102: 105043, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447275
10.
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
J Natl Cancer Inst
; 116(1): 69-80, 2024 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676829
11.
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer.
Cancer Treat Rev
; 112: 102496, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36563600
12.
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
JAMA Oncol
; 9(4): 490-499, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36602784
13.
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
J Natl Cancer Inst
; 115(3): 332-336, 2023 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36576009
14.
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
JAMA Oncol
; 9(6): 835-840, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37103927
15.
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.
Nat Commun
; 14(1): 1157, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36859416
16.
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
JAMA Oncol
; 9(6): 841-846, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37103916
17.
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.
Clin Cancer Res
; 29(24): 5217-5226, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37888299
18.
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report.
Front Oncol
; 12: 1009352, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36425558
19.
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.
Clin Cancer Res
; 28(1): 137-149, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34593528
20.
Gene expression profiles of breast cancer metastasis according to organ site.
Mol Oncol
; 16(1): 69-87, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34051058